Boehringer Ingelheim to acquire Labor Dr Merk & Kollegen EP News Bureau Dec 9, 2020 Transaction expands Boehringer Ingelheim’s R&D and clinical manufacturing capabilities with a site focused predominantly on…
China has highest PD-1/PD-L1 combination immuno-oncology therapies clinical trials growth:… EP News Bureau Nov 30, 2020 Between 2017 and 2019, the number of clinical trials initiated for PD-1/PD-L1 targeted combination therapies increased…
Gilead and Jounce Therapeutics sign exclusive license pact for novel immunotherapy program EP News Bureau Sep 1, 2020 Jounce will lead the development of JTX-1811 through IND clearance, and thereafter, Gilead will have the sole right to develop…
